Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tramadolo

Contramal, Fortradol, Tralodie e altri

Bibliografia - Quali fonti bibliografiche per Tramadolo?

  1. Agenzia Italiana del Farmaco – AIFA, 2013, Patrol - Riassunto caratteristiche di prodotto.

  2. Agenzia Italiana del Farmaco – AIFA, 2013a, Tramadolo EG - Riassunto caratteristiche di prodotto.

  3. Agenzia Italiana del Farmaco – AIFA, 2014, Prontalgin - Riassunto caratteristiche di prodotto.

  4. Agenzia Italiana del Farmaco – AIFA, 2014a, Contramal - Riassunto caratteristiche di prodotto.

  5. Agenzia Italiana del Farmaco – AIFA, 2015, Kolibri - Riassunto caratteristiche di prodotto.

  6. Alemdar M. et al., Clin. Ther., 2007, 29 (7), 1441.

  7. Arcioni R. et al., Anesth. Analg., 2002, 94 (6), 1553.

  8. Aronson J., Meyler’s Side Effects of Analgesics and Anti-inflammatory Drugs, 2009, Elsevier.

  9. Bar-Or D. et al., Eur. Urol., 2012, 61 (4), 736.

  10. Benzon H. et al., Practical Management of Pain, 2013, Elsevier Health Sciences.

  11. Berrocoso E. et al., Psycopharmacology, 2006, 188 (1), 111.

  12. Berrocoso E. et al., Psycopharmacology, 2007, 193 (1), 97.

  13. Bosnjak S. et al., Srp. Arh. Celok. Lek., 2007, 135 (7-8), 453.

  14. Browne B., Linter S., Br. J. Psichiatry, 1987, 151, 210.

  15. Caraceni A. et al., Le complicazioni neurologiche in oncologia, 2007, Springer Science & Business Media.

  16. Coller J.K. et al., Br. J. Clin. Pharmacol., 2012, 74 (5), 835.

  17. Daubin C. et al., Clin. Toxicol. (Phila), 2007, 45 (8), 961.

  18. Dayer P. et al., Drugs, 1997, 53 suppl. 2, 18.

  19. De Backer B. et al., J. Anal. Toxicol., 2010, 34 (9), 599.

  20. De Decker K. et al., Forensic. Sci. Int., 2008, 175 (1), 79.

  21. De Wit D., Koomen-Botman I., Ned. Tijdschr. Geneeskd., 2013, 157 (9), A5610.

  22. Dumo P.A., Kielbasa LA., Pharmacotherapy, 2006, 26 (11), 1654.

  23. Dursteler C. et al., Eur. J. Pain, 2006, 10 (7), 629.

  24. Engindeniz Z. et al., J. Headache Pain., 2005, 6 (3), 143.

  25. Ferini-Strambi L, Marelli S., Expert. Opin. Pharmacother., 2014, 15 (8), 1127.

  26. Food and Drug Administration – FDA, 2009, Ultram - Label Information.

  27. Food and Drug Administration – FDA, 2010, Conzip - Label Information.

  28. Food and Drug Administration – FDA, 2013, Ultracet - Label Information.

  29. Food and Drug Administration – FDA, 2015, FDA drug safety communication. disponibile online http://www.fda.gov/Drugs/DrugSafety/ucm462991.htm.

  30. Food and Drug Administration – FDA, 2017, FDA drug safety communication, disponibile online https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm

  31. Fournier J.P. et al., JAMA Intern. Med., 2015, 175 (2), 186.

  32. Freye E., Levy J., Eur. J. Pain., 2000, 4 (3), 307.

  33. Gobel H., Stadler T., Drugs, 1997, 53 suppl. 2, 34.

  34. Grond S., Sablotzki A., Clin. Pharmacokinet., 2004, 43 (13), 879.

  35. Gullo A., Medicina perioperatoria Terapia intensiva Emergenza, 2003, Springer Science & Business Media.

  36. Hagelberg N.M. et al., Eur. J. Clin. Pharmacol., 2013, 69 (4), 867.

  37. Harati Y. et al., Neurology, 1998, 50 (6), 1842.

  38. Harden R.N. et al., Postgrad. Med., 2013, 125 (4), 191.

  39. Hennies H.H. et al., Arzneimittelforschung, 1988, 38 (7), 877.

  40. Hollingshead J. et al., Cochrane Database Syst. Rev., 2006, 19 (3), CD003726.

  41. Houlihan D.J., Ann. Pharmacother., 2004, 38 (3), 411.

  42. Ivani G., Terapia del dolore nel bambino, 2000, SEE Editrice Firenze.

  43. Jovanovic-Cupi V. et al., Clin. Toxicol. (Phila), 2006, 44 (2), 143.

  44. Kaneko K. et al., Neurosci. Lett., 2014, 562, 28.

  45. Karalliedde L. et al., Adverse Drug Interactions: A Handbook for Prescribers, 2010, CRC Press.

  46. Kaynar M. et al., Urology, 2012, 79 (1), 145.

  47. Kovacs G., Peter L., Neuropsychopharmacol. Hung, 2010, 12 (1), 309.

  48. Lauerma H., Markkula J., J. Clin. Psychiatry, 1999, 60 (4), 241.

  49. Laugesen S. et al., Clin. Pharmacol. Ther., 2005, 77 (4), 312.

  50. Lehmann K.A. et al., Anaesthesist., 1985, 34 (1), 11.

  51. Lehmann K.A. et al., Drugs, 1997, 53 suppl. 2:25.

  52. Lintz W. et al., Arzneimittelforschung, 1981, 31 (11), 1932.

  53. Loughrey M.B. et al., Forensic. Sci. Int., 2003, 134 (2-3), 232.

  54. Lynch T., Price A., American Academy of Family Physicians, 2007, American Family Physicians, disponibile online www.aafp.org

  55. MacLean A.J., Schwartz T.L., Expert. Rev. Neurother., 2015, 15 (5), 469.

  56. Marcus D., Bain P., Effective migraine treatment in pregnant and lactating women: a practical guide, 2009, Springer Science & Business Media.

  57. Makuntus T. et al., Sci. Rep., 2019, 9 (1), 12490.

  58. Marquardt K.A et al., Ann. Pharmacother., 2005, 39 (6), 1039.

  59. Martyn-St. James M. et al., BMC Urology, 2015, 15, 6.

  60. Mockenhaupt M. et al., J. Invest. Dermatol., 2008, 128 (1), 35.

  61. Naslund S., Dahlqvist R., Lakartidningen, 2003, 100 (9), 712.

  62. Neri E. et al., Arch. Dis. Child, 2013, 98 (9), 721.

  63. Niscola P. et al., G. Ital. Nefrol., 2011, 28 (3), 269.

  64. Novelli G.P. et al., Terapia del dolore, 1999, SEE Editrice Firenze.

  65. Petzke F. et al., Support Care Cancer, 2001, 9 (1), 48.

  66. Pittenger C. et al., Psychiatry (Edgmont), 2005, 2 (11), 34.

  67. Planas E. et al., Eur. J. Pharmacol., 2003, 482 (1-3), 223.

  68. Proudfoot A.T., Wright N., BMJ, 1970, 3 (5722), 557.

  69. Rogers K.J., Thornton J.A., Br. J. Pharmacol., 1969, 36 (3), 470.

  70. Rojas-Corrales M.O. et al., Eur. J. Pharmacol., 2005, 511 (1), 21.

  71. Rumack B.H., Am. J. Med., 1983, 75 (5A), 104.

  72. Saarikoski T. et al., Eur. J. Clin. Pharmacol., 2013, 69 (6), 1293.

  73. Sadock B.J. et al., Kaplan & Sadock’s trattamento farmacologico in psichiatria: guida pratica, 2015, Edra Masson.

  74. Salem E.A. et al., J. Sex. Med., 2008, 5 (1), 188.

  75. Sansone R., Sansone L., Psychiatry (Edgmont), 2009, 6 (4), 17.

  76. Scott L.J., Perry C.M., Drugs, 2000, 60 (1), 139.

  77. Senay E.C. et al., Drug Alcohol Depend., 2003, 69 (3), 233.

  78. Shah N.H. et al., Auton. Autacoid. Pharmacol., 2013, 33 (1-2), 1.

  79. Silberstein S.D. et al., Headache, 2005, 45 (10), 1317.

  80. Spiller H.A et al., J. Toxicol. Clin. Toxicol., 1997, 35 (4), 361.

  81. Stamer U.M. et al., Clin. Pharmacol. Ther., 2007, 82 (1), 41.

  82. Tamaskar R. et al., J. Addict. Dis., 2003, 22 (4), 5.

  83. Tashakori A., Afshari R., Clin. Toxicol. (Phila), 2010, 48 (4), 337.

  84. Zanger U.M. et al., Naunyn. Schmiedebergs Arch. Pharmacol., 2004, 369 (1), 23.